Gemphire Therapeutics now has a consensus rating of "Buy" and an average target price of $24.33. Jefferies Group LLC reduced their price objective on shares of Gemphire Therapeutics from $32.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday. It focused on developing and commercializing therapies for the treatment of dyslipidemia.
"In ROYAL-1, gemcabene met the primary endpoint and demonstrated a statistically significant lowering in LDL-C, although the magnitude of LDL-C lowering was less than observed in certain prior studies of gemcabene", stated Dr. Gemphire Therapeutics Inc.is headquartered in Northville, Michigan.
Several other analysts have also commented on the stock. Piper Jaffray Companies started coverage on Gemphire Therapeutics in a research note on Monday, April 10th. The stock has a consensus rating of "Buy" and a consensus price target of $24.33. Finally, Canaccord Genuity reiterated a "buy" rating and set a $17.00 target price on shares of Gemphire Therapeutics in a research report on Wednesday, May 31st.
Among 6 analysts covering Iamgold Corp (TSE:IMG), 2 have Buy rating, 3 Sell and 1 Hold. The stock presently has an average rating of "Buy" and a consensus target price of $26.67.
Gemphire Therapeutics (GEMP) traded up 7.1278% on Tuesday, hitting $8.6345. Gemphire Therapeutics has $25 highest and $15 lowest target. With the last stock price close down -19.56% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the same time. The company's market capitalization is $78.33 million.
Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.18. Jefferies Group analyst M. Andrews now expects that the company will post earnings per share of ($1.92) for the year, down from their previous forecast of ($1.87).
ILLEGAL ACTIVITY WARNING: "Gemphire Therapeutics Inc". More interesting news about Gemphire Therapeutics Inc (NASDAQ:GEMP) were released by: Nasdaq.com and their article: "Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 9.7%" published on March 23, 2017 as well as Streetinsider.com's news article titled: "Gemphire Therapeutics (GEMP) Reports Top-Line Data from COBALT-1 Phase 2b ..." with publication date: June 28, 2017. If you are viewing this story on another site, it was illegally stolen and republished in violation of global copyright & trademark laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/08/11/gemphire-therapeutics-inc-gemp-stock-rating-lowered-by-zacks-investment-research-updated-updated.html. Finally, Norris Perne & French LLP MI acquired a new stake in Gemphire Therapeutics during the first quarter valued at about $110,000. Exchange Capital Management Inc. purchased a new stake in shares of Gemphire Therapeutics during the first quarter worth about $444,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Gemphire Therapeutics during the first quarter worth approximately $1,581,000. Renaissance Technologies LLC purchased a new stake in shares of Gemphire Therapeutics during the first quarter worth about $184,000. Northpointe Capital LLC bought a new stake in Gemphire Therapeutics during the second quarter valued at about $3,472,000.
A number of hedge funds have recently made changes to their positions in the company.
Including today's unusual volume, Gemphire Therapeutics Inc.'s stock is performing at 2.81% on the year.